Beckman Blood Test Approved by FDA
- Share via
The Food and Drug Administration cleared a Beckman Coulter Inc. blood test as an aid in managing osteoporosis and Paget’s disease, the Fullerton company said Wednesday.
The new Access Ostase test gives physicians and patients a more timely method to evaluate therapy to help prevent or treat osteoporosis, a disease that weakens the bones, and Paget’s disease, a crippling bone disorder, the company said.
The company’s stock closed Wednesday at $63.13, up 13 cents a share, on the New York Stock Exchange.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
